Evidence map›Paper›PMID 41697602›Full record

ArticleUpdates in surgery2026

Predictors of disease progression in pancreatic neuroendocrine tumors after surgery.

Eva Maria Dobrindt, Janina Maren Krömer, Martina T Mogl, Agata Dukaczewska, Charlotte Friederieke Müller-Debus, Peter Steinhagen, Uli Fehrenbach, Thomas Malinka, Johann Pratschke, Frederike Butz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eva Maria Dobrindt *Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Janina Maren Krömer *Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Martina T MoglDepartment of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Agata DukaczewskaDepartment of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Charlotte Friederieke Müller-DebusDepartment of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Peter SteinhagenDepartment of Hepatology and Gastroenterology, Campus Charité Mitte, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Uli FehrenbachDepartment of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Thomas MalinkaDepartment of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Johann PratschkeDepartment of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Frederike ButzDepartment of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. frederike.butz@charite.de.ORCID http://orcid.org/0000-0002-5963-1558

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of tumors that exhibit a range of biological behaviors, from indolent to aggressive. Identifying prognostic factors for pNETs is essential for risk stratification and personalized treatment planning. Clinicopathological data of stage I to III patients who underwent pancreatic resection and were treated for pNET at an ENETS Center of Excellence from 2009 to 2023 were analyzed retrospectively. 89 pNET patients were included (45 female, 44 male). Proximal pNETs had higher proportions of lymph node metastases (48.4% vs. 17.2%, p = 0.002) and shorter progression-free survival (PFS) compared to distal tumors (5-year PFS 56.2% vs. 85.0%, p = 0.003). Subdivision of G2 into G2a (Ki67 3-<10%) and G2b (Ki67 10-20%) identified shorter PFS in G2b than in G1 and G2a tumors (5-year PFS G1: 93.6%, G2a: 73.5%, G2b: 34.3%, p < 0.001) while PFS did not differ between G2b and G3 (34.3% vs. 28.6%, p = 0.192). Cox regression analyses revealed tumor grading (G2b: HR 8.396 (2.025-34.081), p = 0.003; G3: HR 17.649 (3.912-79.627), p < 0.001) and lymph node metastases (HR 2.657 (1.040-6.789), p = 0.041) as risk factors for shorter PFS.Tumor grading and lymph node metastases are independent predictors of postoperative disease progression in pNET patients without distant metastases. Subdividing G2 tumors into G2a and G2b improves prognostic discrimination, with G2b tumors demonstrating outcomes comparable to G3 tumors. These findings support the incorporation of refined grading into treatment and follow-up considerations.

Indexed as

Neuroendocrine TumorsPancreatectomyPancreatic NeoplasmsAdultAgedDisease ProgressionFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisProgression-Free SurvivalRetrospective StudiesOncological outcomePancreatic neuroendocrine neoplasmsPancreatic neuroendocrine tumorsPrognostic factorsRisk stratification

Identifiers

PMID41697602
PMCPMC13249762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.